The stock of Nivalis Therapeutics Inc (NASDAQ:NVLS) hit a new 52-week low and has $2.79 target or 3.00% below today’s $2.88 share price. The 6 months bearish chart indicates high risk for the $44.55 million company. The 1-year low was reported on Nov, 29 by Barchart.com. If the $2.79 price target is reached, the company will be worth $1.34 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 1.45M shares traded hands or 1964.12% up from the average. Nivalis Therapeutics Inc (NASDAQ:NVLS) has risen 39.51% since April 26, 2016 and is uptrending. It has outperformed by 34.25% the S&P500.
Analysts await Nivalis Therapeutics Inc (NASDAQ:NVLS) to report earnings on March, 6. They expect $-0.58 EPS, down 38.10% or $0.16 from last year’s $-0.42 per share. After $-0.48 actual EPS reported by Nivalis Therapeutics Inc for the previous quarter, Wall Street now forecasts 20.83% negative EPS growth.
According to Zacks Investment Research, “Nivalis Therapeutics, Inc. is a pharmaceutical company. The company is engaged in discovery, development and commercialization of molecule therapeutics for cystic fibrosis. Nivalis Therapeutics, Inc. is headquartered in Boulder, Colorado.”
More recent Nivalis Therapeutics Inc (NASDAQ:NVLS) news were published by: Marketwatch.com which released: “/quotes/zigman/3870025/realtime” on July 13, 2009. Also Globenewswire.com published the news titled: “Nivalis Therapeutics Announces Pricing of Its Initial Public Offering” on June 17, 2015. Globenewswire.com‘s news article titled: “Nivalis Therapeutics Appoints David Rodman, MD as Chief Medical Officer and …” with publication date: April 18, 2016 was also an interesting one.
NVLS Company Profile
Nivalis Therapeutics, Inc., incorporated on March 30, 2007, is a clinical-stage pharmaceutical company. The Firm discovers, develops and commercializes product candidates for patients with cystic fibrosis (CF). The Firm focuses on utilizing its S-nitrosoglutathione reductase (GSNOR) inhibitor portfolio to develop therapeutics for other diseases. The Firm operates through discovering and development of potential drugs segment. The Company’s activities are focused on discovery and development of its portfolio of GSNOR inhibitors, including N91115. GSNOR inhibitor portfolio includes other compounds with differing chemical structures and properties suitable for oral, inhaled, injectable and topical administration. The Company’s drug candidate portfolio consists of multiple compounds, which are designed for oral, intravenous (IV) or inhaled administration.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.